February 9, 2022 -- BioSkryb Genomics and ALS Automated Lab Solutions have announced a U.S. distribution agreement to power comprehensive single-cell plus spatial genomic analysis. The agreement was signed in December 2021. The partnership will develop single-cell genome analysis from intact tissue samples.
The distribution agreement combines BioSkryb's proprietary ResolveDNA technology with ALS' CellCelector platform to drive single-cell genomic applications where the genome context matters. Now, researchers and clinicians can perform single-cell genomics from cells isolated at a specific location, according to the firms.
The companies are collaborating to extend the analysis of intact tissue specimens, where a single cell is selected from the organized cell structure and analyzed with high-resolution genome analysis. This process is designed to maintain the cell context of the original environment and provide critical information for many fields, including oncology, cardiology, neurology, immunology, and preimplantation genetic testing, that could help guide diagnostics and treatment decisions.
BioSkryb's ResolveDNA products incorporate proprietary primary template-directed amplification (PTA) technology, which aids in producing high-quality gene sequencing data. BioSkryb Genomics will launch an early access program for researchers to acquire the combined ALS CellCelector and ResolveDNA workflow.
Financial details of the agreement were not disclosed.
ALS Automated Lab Solutions develops, manufactures, and sells automated solutions for life sciences. BioSkryb Genomics is a venture-backed developer of genomic amplification technologies.